Skip to main content
ZYME
NASDAQ Life Sciences

$200M Buyback Authorized, Doubling Down After $125M Program Wrapped

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$26.3
Mkt Cap
$1.826B
52W Low
$18.2
52W High
$31.97
52W Position info
45% above low
Off High info
18% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

ZYME sits 45% above its 52-week low of $18.2.

Summary

Zymeworks' board authorized a second 2026 repurchase program of up to $200M, after fully completing the initial $125M program. Management expects to actually spend about $140M through 2028, funded from the balance sheet plus the $55M Roche upfront expected before year-end and a potential $100M TRELEGY ELLIPTA milestone in Q1 2027. At roughly $26 a share and 68.7M shares outstanding, the authorization covers a meaningful slice of the float, though the company retains full discretion on pace and can suspend it at any time. The buyback follows a strong stretch: FDA approval of Ziihera in first-line HER2+ GEA triggered a $250M Jazz milestone, Q3 revenue came in at $256.5M with $173.7M of net income, and the $929M Theravance acquisition closed in September. Watch HSR clearance for the Roche collaboration, which gates the $55M upfront and the start of repurchases before year-end.

At the time of this announcement, ZYME was trading at $26.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $18.20 to $31.97. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

ZYME - Latest Insights

ZYME
Nov 09, 2026, 4:10 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $30.81
Real-time Price: $26.30 info
Change: -$4.51 (-15%) info
Market Cap: $1.826B info
ZYME
Nov 09, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $30.81
Real-time Price: $26.30 info
Change: -$4.51 (-15%) info
Market Cap: $1.826B info
ZYME
Nov 09, 2026, 4:05 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $30.81
Real-time Price: $26.30 info
Change: -$4.51 (-15%) info
Market Cap: $1.826B info
ZYME
Oct 24, 2026, 2:30 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $28.55
Real-time Price: $26.30 info
Change: -$2.25 (-8%) info
Market Cap: $1.826B info
ZYME
Oct 23, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $28.99
Real-time Price: $26.30 info
Change: -$2.69 (-9%) info
Market Cap: $1.826B info